The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass
Open accessAbstract
Adenosine 5′-monophosphate-activated protein kinase (AMPK), a regulator of energy homeostasis, has a central role in mediating the appetite-modulating and metabolic effects of many hormones and antidiabetic drugs metformin and glitazones. The objective of this study was to determine if AMPK can be activated in osteoblasts by known AMPK modulators and if AMPK activity is involved in osteoblast function in vitro and regulation of bone mass in vivo. ROS 17/2.8 rat osteoblast-like cells were cultured in the presence of AMPK activators (AICAR and metformin), AMPK inhibitor (compound C), the gastric peptide hormone ghrelin and the beta-adrenergic blocker propranolol. AMPK activity was measured in cell lysates by a functional kinase assay and AMPK protein phosphorylation was studied by Western Blotting using an antibody recognizing AMPK Thr-172 residue. We demonstrated that treatment of ROS 17/2.8 cells with AICAR and metformin stimulates Thr-172 phosphorylation of AMPK and dose-dependently increases its activity. In contrast, treatment of ROS 17/2.8 cells with compound C inhibited AMPK phosphorylation. Ghrelin and propranolol dose-dependently increased AMPK phosphorylation and activity. Cell proliferation and alkaline phosphatase activity were not affected by metformin treatment while AICAR significantly inhibited ROS 17/2.8 cell proliferation and alkaline phosphatase activity at high concentrations. To study the effect of AMPK activation on bone formation in vitro, primary osteoblasts obtained from rat calvaria were cultured for 14-17 days in the presence of AICAR, metformin and compound C. Formation of ‘trabecular-shaped’ bone nodules was evaluated following alizarin red staining. We demonstrated that both AICAR and metformin dose-dependently increase trabecular bone nodule formation, while compound C inhibits bone formation. When primary osteoblasts were co-treated with AICAR and compound C, compound C suppressed the stimulatory effect of AICAR on bone nodule formation. AMPK is a αβγ heterotrimer, where α is the catalytic subunit. RT-PCR analysis of AMPK subunits in ROS17/2.8 osteoblastic cells and in mouse tibia showed that the AMPKα1 subunit is the dominant isoform expressed in bone. We analysed the bone phenotype of 4 month-old male wild type (WT) and AMPKα1−/− KO mice using micro-CT. Both cortical and trabecular bone compartments were smaller in the AMPK α1-deficient mice compared to the WT mice. Altogether, our data support a role for AMPK signalling in skeletal physiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Endocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554
Leptin Inhibits Bone Formation through a Hypothalamic Relay
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Leptin regulation of bone resorption by the sympathetic nervous system and CART
Elefteriou, F., Ahn, J. D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo, H., Richards, W. G., Bannon, T. W., Noda, M., et al. (2005) · Nature · doi:10.1038/nature03398 · Cited by 1,311 · cited 5×
“While communication between fat and bone was debated for a long time, new evidence has emerged with the discovery that the adipocytesecreted hormone leptin inhibits bone formation through hypothalamic and sympathetic nervous system (SNS) relays [1,2].”
BackgroundResultInfluentialJørgensen, S. B., Viollet, B., Andreelli, F., Frøsig, C., Birk, J. B., Schjerling, P., Vaulont, S., Richter, E. A., & Wojtaszewski, J. F. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306205200 · Cited by 553
Self-citationThe AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity
Viollet, B., Andreelli, F., Jørgensen, S. B., Perrin, C., Geloen, A., Flamez, D., Mu, J., Lenzner, C., Baud, O., Bennoun, M., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16567 · Cited by 499
Self-citationLeptin directly regulates bone cell function in vitro and reduces bone fragility in vivo
Cornish, J., Callon, K., Bava, U., Lin, C., Naot, D., Hill, B., Grey, A., Broom, N., Myers, D., Nicholson, G., et al. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750405 · Cited by 472
The Glycogen-Binding Domain on the AMPK β Subunit Allows the Kinase to Act as a Glycogen Sensor
McBride, A., Ghilagaber, S., Nikolaev, A., & Hardie, D. G. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.008 · Cited by 432
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
Idris, A. I., van 't Hof, R. J., Greig, I. R., Ridge, S. A., Baker, D., Ross, R. A., & Ralston, S. H. (2005) · Nature Medicine · doi:10.1038/nm1255 · Cited by 356
Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
LeBrasseur, N. K., Kelly, M., Tsao, T.-S., Farmer, S. R., Saha, A. K., Ruderman, N. B., & Tomas, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2005 · Cited by 276
Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models
Viollet, B., Andreelli, F., Jørgensen, S. B., Perrin, C., Flamez, D., Mu, J., Wojtaszewski, J. F. P., Schuit, F. C., Birnbaum, M., Richter, E., et al. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310216 · Cited by 241 · cited 1×
“No known metabolic changes were detected in AMPK α1-deficient mice that could explain our skeletal defects[50,71].”
BackgroundSelf-citationGut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis
Thorens, B., & Larsen, P. J. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/01.mco.0000134368.91900.84 · Cited by 73
Cited by
Ghrelin: much more than a hunger hormone
Pradhan, G., Samson, S. L., & Sun, Y. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328365b9be · Cited by 288
Pantovic, A., Krstic, A., Janjetovic, K., Kocic, J., Harhaji-Trajkovic, L., Bugarski, D., & Trajkovic, V. (2013) · Bone · doi:10.1016/j.bone.2012.10.024 · Cited by 262
Pereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137
Self-citationMetabolic regulation by biomaterials in osteoblast
Kang, Z., Wu, B., Zhang, L., Liang, X., Guo, D., Yuan, S., & Xie, D. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1184463 · Cited by 15
Metadata
- Authors
- Shah, M., Kola, B., Bataveljic, A., Arnett, T. R., Viollet, B., Saxon, L., Korbonits, M., & Chenu, C.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 47
- Issue
- 2
- Pages
- 309-319
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2151966001
- Cited by
- 195
- References
- 13
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.